Currently, prevailing evidence have identified cholinergic and oxidative pathways as important therapeutic targets for abating ketamine-induced schizophrenia-like behavior. Thus, this study evaluated the ability of hesperidin, a naturally occurring antioxidant and neuroprotective flavonoid, to prevent and reverse ketamine-induced schizophrenia-like behaviors and changes in cholinergic, oxidative and nitrergic status in mice. Forty-eight male Swiss mice were allotted into the preventive and reversal studies with 4 groups (n = 6) each. In the preventive study, groups 1 and 2 received vehicle (10 mL/kg/p.o./day), while groups 3 and 4 had hesperidin (100 mg/kg/p.o./day) for 14 days, but ketamine (20 mg/kg/i.p./day) was concurrently given to groups 2 and 4 from days 8-14. In the reversal study, groups 1 and 3 received vehicle, groups 2 and 4 were pretreated with ketamine for 14 days. Nevertheless, groups 3 and 4 additionally received hesperidin from days 8-14. Thereafter, schizophrenia-like behavior from exploratory activity, open-field (positive symptoms), Y-maze (cognitive symptoms) and social interaction (negative symptoms) tests were evaluated. Brain levels of oxidative/nitrergic (glutathione, superoxide-dismutase, malondialdehyde and nitrite levels) and cholinergic (acetylcholinesterase activity) markers were measured in the prefrontal-cortex, striatum and hippocampus. Hesperidin prevents and reverses ketamine-induced hyperactivities, social withdrawal and cognitive impairment. Also, hesperidin prevented and reversed ketamine-induced decrease in glutathione and superoxide-dismutase levels in the prefrontal-cortical, striatal and hippocampal brain regions in mice. Consequently, hesperidin attenuated ketamine-induced increase in malondialdehyde, nitrite levels and acetylcholinesterase activities in the prefrontal-cortex, striatum and hippocampus, respectively. The study showed that hesperidin prevents and reverses ketamine-induced schizophrenia-like behavior through inhibition of oxidative/nitrergic stress and acetylcholinesterase activity in mice brains. Therefore, these findings suggest that hesperidin dietary supplementation could provide natural nutritional intervention to protect against epigenetic-induced mental ill-health like schizophrenia, and thus serve as an important agent for nutritional psychiatry.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brainresbull.2021.10.007DOI Listing

Publication Analysis

Top Keywords

ketamine-induced schizophrenia-like
12
schizophrenia-like behavior
12
hesperidin
9
cholinergic oxidative
8
study groups
8
groups received
8
received vehicle
8
days 8-14
8
glutathione superoxide-dismutase
8
malondialdehyde nitrite
8

Similar Publications

The amino acid metabolism pathway of peripheral T lymphocytes and ketamine-induced schizophrenia-like phenotype.

J Psychiatry Neurosci

December 2024

West China School of Basic Medical Sciences and Forensic Medicine, Sichuan University, Chengdu, China

Article Synopsis
  • - The study investigates how changes in peripheral adaptive immune cells affect metabolic profiles in a ketamine-treated mouse model of schizophrenia, suggesting a link between immune responses and mental health issues.
  • - Using flow cytometry and advanced metabolomics techniques, researchers found an increase in CD3 T cells and notable alterations in amino acid metabolism, particularly elevated levels of glycine, alanine, asparagine, and aspartic acid.
  • - Although the research highlights the role of peripheral amino acid metabolism in ketamine-induced schizophrenia symptoms, it has yet to pinpoint the specific metabolic pathways responsible for these changes.
View Article and Find Full Text PDF

Effective action of silymarin against ketamine-induced schizophrenia in male mice: Insight into the biochemical and molecular mechanisms of action.

J Psychiatr Res

November 2024

DELSU Joint Canada-Israel Neuroscience and Biopsychiatry Laboratory, Department of Pharmacology, Faculty of Basic Medical Sciences, College of Health Sciences, Delta State University, Abraka, Delta State, Nigeria.

Background: Neurochemical dysregulations resulting from N-methyl-D-aspartate hypofunction (NMDA), are exacerbated by neuroimmune and oxidative stress and are known risk factors for neuropsychiatric disorders like schizophrenia-like diseases. Here, we investigate the protective and curative effects, and mechanisms of silymarin, a polyphenolic flavonoid with neuroprotective functions in preventive-reversal model of ketamine, an NMDA antagonist in mice.

Methods: Mice were grouped into 6 cohorts (n = 9).

View Article and Find Full Text PDF

Repeated administration of ketamine (KET) has been used to model schizophrenia-like symptomatology in rodents, but the psychotomimetic neurobiological and neuroanatomical underpinnings remain elusive. In parallel, the unmet need for a better treatment of schizophrenia requires the development of novel therapeutic strategies. Cannabidiol (CBD), a major non-addictive phytocannabinoid has been linked to antipsychotic effects with unclear mechanistic basis.

View Article and Find Full Text PDF
Article Synopsis
  • * The study analyzed different groups of mice, including those infected with toxoplasmosis and those induced with schizophrenia-like symptoms through ketamine, observing their behavior and brain changes.
  • * Results showed that both toxoplasmosis and ketamine decreased antioxidant levels and altered NMDAR expression, indicating potential targets for future therapies aimed at cognitive and neurological impairments related to these conditions.
View Article and Find Full Text PDF

Background: Adverse experiences due to early life stress (ELS) or parental psychopathology such as schizophrenia (SZ) have a significant implication on individual susceptibility to psychiatric disorders in the future. However, it is not fully understood how ELS affects social-associated behaviors as well as the developing prefrontal cortex (PFC).

Objective: The aim of this study was to investigate the impact of ELS and ketamine induced schizophrenia like symptoms (KSZ) on anhedonia, social behavior and anxiety-like behavior.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!